Overview of Non-Muscle Invasive Bladder Cancer (NMIBC)
Experts in urology discuss the importance of evaluation to accurately identify the stage and grade of NMIBC, which plays a crucial role in determining the risk category focusing on the distinction between low and high-grade tumors and the significance for each patient with NMIBC.
EP: 1.Overview of Non-Muscle Invasive Bladder Cancer (NMIBC)
EP: 2.Appropriate Risk Stratification Intermediate and high-risk Risk Classification
EP: 3.Adapting Urology Practices in the Face of BCG Shortages
EP: 4.Initial Treatment Selection for NMIBC in the Era of BCG Shortage
EP: 5.Strategies for the Management of Recurrent Low-Grade Bladder Tumors
EP: 6.Navigating Treatment Options for Elderly Patients with High-Risk NMIBC
EP: 7.Investigational Novel Strategies in High-Risk BCG-Unresponsive NMIBC
EP: 8.Review of Cretostimogene Grenadenorepvec (CG) Clinical Trials in High-risk BCG-unresponsive NMIBC
EP: 9.Emerging Treatments High-Risk BCG-Unresponsive NMIBC setting
EP: 10.Treatment Strategies for BCG-Unresponsive NMIBC
EP: 11.Novel Approaches and Recent Trial Updates in Intermediate-risk NMIBC
EP: 12.Forward Looking NMIBC Treatment Advancements and Needs in 2024
This is a synopsis of the Viewpoints video series featuring moderator, Sam S. Chang, MD, MBA, from Vanderbilt University School of Medicine, and panelists Gary Steinberg, MD, FACS, from Rush University Medical Center, Mark Tyson, MD, of Mayo Clinic Phoenix, Roger Li, MD, from Moffitt Cancer Center, and Sandip M. Prasad, MD, MPhil, of Morristown Medical Center.
In the inaugural episode of Urology Times® Viewpoints, Dr. Sam Chang, a urologist at Vanderbilt University in Nashville, Tennessee, leads a panel of distinguished experts in discussing the latest in NMIBC. The panel includes Dr. Gary Steinberg from Rush University in Chicago, Dr. Sandip Prasad from Morristown Medical Center in New Jersey, Dr. Mark Tyson, a urologic oncologist at Mayo Clinic in Scottsdale, Arizona, and Dr. Roger Lee, a urologic oncologist at the Moffitt Cancer Center in Tampa, Florida.
The focus of the discussion is on accurately identifying the stage and grade of NMIBC, crucial for determining the appropriate risk category for each patient. The panel emphasizes the distinction between low-grade tumors, which are generally favorable and relatively indolent in terms of their progression, and high-grade tumors, which carry the potential for invasiveness and even metastasis. Staging in NMIBC is classified as either stage TA, indicating superficial disease, or T1, suggesting invasive disease. These classifications help define low, intermediate, and high-risk diseases. Furthermore, the panelists delve into the nuances of upper versus lower tract diseases. They highlight the more aggressive nature and higher risk associated with upper tract disease, underscoring the importance of early detection and accurate staging. They also discuss the genetic similarities and differences between upper and lower tract diseases and how these factors influence therapeutic interventions and future treatment strategies.
The episode serves as a comprehensive guide for healthcare professionals in understanding the complexities of NMIBC, from staging and grading to the implications of tumor location and the significance of genetic factors in treatment planning.
*Video synopsis is AI-generated and reviewed by Urology Times® editorial staff.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Cell therapy TARA-002 shows initial promise in NMIBC
April 9th 2024"This encouraging anti-tumor activity coupled with a favorable safety profile and mode of administration that is both convenient and familiar to urologists indicates that, if confirmed in future studies, TARA-002 could potentially play a meaningful role in NMIBC treatment in the future," says Timothy D. Lyon, MD.
